Vectura Group plc confirmed that the company's partner, Sandoz, has received marketing authorisation in Hungary for AirFluSal Forspiro (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD). Hungary has approved the 50-500µg dosage form for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD in adults. The product's safety, efficacy and equivalence have been proven in multiple clinical trials 1,2.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99.06 CHF | +0.16% | +0.77% | +16.72% |
07:28am | Novartis Reports Higher H1 Attributable Net Income, Net Sales | MT |
07:16am | Novartis raises 2024 profit guidance for second time | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.72% | 228B | |
+55.35% | 815B | |
+31.64% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+15.51% | 247B | |
+16.54% | 180B | |
+4.31% | 170B | |
+2.52% | 126B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Sandoz Receives Marketing Authorisation in Hungary for AirFluSal Forspiro